High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis

被引：0
作者：
Mehrdad Rostami
Hassan Mansouritorghabeh
Mohammad Parsa-Kondelaji
机构：
[1] Mashhad University of Medical Sciences,Hematology and Blood Banking
[2] Mashhad University of Medical Sciences,Central Diagnostic Laboratories, Ghaem Hospital
来源：
Clinical and Experimental Medicine | 2022年 / 22卷
关键词：
COVID-19; Thrombosis; VWF:Ag; VWF:AC; VWF:Co; ADAMTS-13; Factor VIII level;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The SARS-CoV-2 virus has spread to all corners of the world. Thrombosis is the cause of organ failure and subsequent death in COVID-19. The pathophysiology of thrombosis in COVID-19 needs to be further explored to shed light on its downside. For this reason, this meta-analysis of Von Willebrand Factor profile (VWF: Ag, VWF: activity, VWF: RCo), ADAMTS-13, and factor VIII levels in COVID-19 was performed. To obtain data on the status of the aforementioned hemostatic factors, a systematic literature review and meta-analysis were performed on COVID-19. After reviewing the evaluation of 348 papers, 28 papers included in the meta-analysis, which was performed using STATA. The analysis showed an increase in VWF: Ag levels in COVID‐19 patients. VWF: Ac was higher in all COVID-19 patients, while it was lower in the COVID‐19 ICU patients. The pooled mean of VWF: RCO in all patients with COVID-19 was 307.94%. In subgroup analysis, VWF: RCO was significantly higher in ICU patients than in all COVID-19 patients. The pooled mean of ADAMTS-13 activity was 62.47%, and 58.42% in ICU patients. The pooled mean of factor VIII level was 275.8%, which was significantly higher in ICU patients with COVID-19 than all patients with COVID-19. Levels of VWF: Ag, VWF: activity, VWF: ristocetin, and factor VIII are increased in patients with COVID-19. The elevated levels in ICU patients with COVID-19 suggest that these markers may have prognostic value in determining the severity of COVID-19. New therapeutic programs can be developed as a result.
引用
收藏
页码：347 / 357
页数：10
相关论文
共 149 条
[11]  
Pan JY(2020)Complement activation in patients with COVID-19: a novel therapeutic target J Allergy Clin Immunol 146 215-1275
[12]  
McFadyen JD(2020)D-dimer level in COVID-19 infection: a systematic review Expert Rev Hematol 13 1265-586
[13]  
Stevens H(2020)Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients J Thromb Thrombolysis 50 580-3777
[14]  
Peter K(2003)The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome Blood J Am Soc Hematol 101 3765-784
[15]  
Middeldorp S(1998)Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection Am J Respir Crit Care Med 157 776-494
[16]  
Coppens M(2001)Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura Nature 413 488-147
[17]  
van Haaps TF(2018)Inflammation, von Willebrand factor, and ADAMTS13 Blood 132 141-651
[18]  
Bikdeli B(2018)The role of ADAMTS-13 in the coagulopathy of sepsis J Thromb Haemost 16 646-1342
[19]  
Madhavan MV(2020)Role of von Willebrand factor and ADAMTS-13 in the pathogenesis of thrombi in SARS-CoV-2 infection: time to rethink Thromb Haemost 120 1339-863
[20]  
Jimenez D(2020)Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients Intern Emerg Med 15 861-1805
12345678910